LYEL News and Press, Lyell Immunopharma Inc. From 06/16/23

2023-06-16 10:47:04 ET Shares of Lyell Immunopharma (NASDAQ: LYEL) were up 39% for the week as of early Friday morning, according to data provided by S&P Global Market Intelligence . The clinical-stage biotech , which ended last week's trading at $2.78, rose to as high a...

2023-06-14 23:41:18 ET It was another wild ride in the stock market today. Whether you were trading penny stocks or Tesla, the thing weighing on everyone’s conscience was the outcome of the June Fed meeting. Another “small” thing traders and investors were focused o...

SOUTH SAN FRANCISCO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that members of its senior management team wi...

2023-05-16 17:23:00 ET Gainers: National Western Life Group ( NWLI ) +17% . Extreme Networks ( EXTR ) +7% . Lyell Immunopharma ( LYEL ) +5% . PacWest Bancorp ( PACW ) +5% . Spruce Biosciences ( SPRB ) +5% . Losers: EVgo&#...

Two phase 1 clinical trials recruiting patients at 14 sites across the US; nine sites for LYL797, a ROR-1-targeted chimeric antigen receptor T cell (CAR-T) product candidate, and five sites for LYL845, a tumor infiltrating lymphocyte (TIL) product candidate Cash, cash equivalents and marketab...

Cash, cash equivalents and marketable securities of $710.3 million as of December 31, 2022 supports advancing robust pipeline into 2026, through multiple clinical milestones Phase 1 clinical trials initiated for two wholly-owned product candidates for the treatment of solid tumors ...

Summary Lyell Immunopharma is a US biotechnology developer of innovative therapies for various types of cancer. Shares are falling in trend and headwinds could continue due to lost glamour for the portfolio. LYEL stock should not earn much more than a Sell rating. But when there's n...

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced today that members of its senior management team will pre...

SOUTH SAN FRANCISCO, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced that Lynn Seely, MD, a member of the companyȁ...

SOUTH SAN FRANCISCO, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, today announced that members of its senior management team w...